Adrenomedullin, a hormone first identified in an adrenal medullary tumor, disrupts the effect of insulin on the endothelium of blood vessels, leading to insulin resistance linked to obesity and type 2 diabetes. The clue to this discovery lies in a molecular pathway that could be blocked to restore insulin function.
Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock by 30% after it had largely recovered from a terminated deal with France’s Théa Open Innovation last year.
Novartis AG is paying nearly $1 billion up front to buy privately held Anthos Therapeutics Inc. in a deal that eventually could top out around $3.1 billion. Novartis, coming back to where it started as it and Blackstone Life Sciences founded Anthos in 2019, is entering a crowded space.
Be (not too) still my heart: Kestra Medical Technologies Ltd., maker of a wearable cardioverter defibrillator for patients at high risk of cardiac arrest, filed an S-1 with the U.S. SEC on Feb. 9 to raise $100 million in an IPO. Kestra will be the fourth med-tech company to file for an IPO in 2025, setting a pace well ahead of the last three years. U.s.car
Microglia play a crucial role in neuroinflammation after ischemic brain injury. Previous data have shown that leukocyte immunoglobulin-like receptor B4 (LILRB4) was upregulated in mice after middle cerebral artery occlusion (MCAO), but the role it plays here is not well understood. The role LILRB4 plays in ischemic brain injury was thus investigated. LILRB4 expression was measured in mice at different time points after MCAO.
Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock by 30% after it had largely recovered from a terminated deal with France’s Théa Open Innovation last year.
A 1,000-person study using Heartflow Inc. technology demonstrated that findings of coronary plaque on heart CT scans could indicate which patients were at risk of cardiovascular events up to seven years in the future – potentially providing a road map toward screening for heart disease, the leading cause of death for both men and women in the U.S. and worldwide.
The U.S. national coverage analysis for transcatheter tricuspid valve replacement drew support from cardiologists and device makers alike, but the Medical Device Manufacturers Association is urging CMS to plan ahead in its final coverage memo and consider the coverage needs outside the confines of the existing U.S. FDA-approved device.
The med tech patent wars conscripted another two companies via a patent infringement lawsuit between Inari Medical Inc. and Imperative Care Inc. — a struggle that is playing out in a California district court.
Early dysfunction of the endothelial/blood-brain barrier (BBB) is involved in the pathogenesis of cerebral small vessel disease (SVD), which is a contributor to about 50% of dementias. Sphingosine-1-phosphate (S1P) is a sphingolipid that regulates the BBB integrity when bound to its receptor S1P1 on endothelial cells.
RSS
